Efficacy and safety of step-down therapy with ciclesonide once-daily and beta2-agonist tulobuterol patch in asthma patients receiving salmeterol/fluticasone propionate diskus: multicenter study
Not Applicable
Recruiting
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000003023
- Lead Sponsor
- Hiroshima Allergy Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1)addition or dose-change of antiasthma medications (except for salmeterol/fluticasone propionate diskus) within previous 3 months 2)use of ciclesonide and beta2-agonist tulobuterol patch within previous 3 months 3)corresponding to contraindication on accompanied note of study medication 4)difficult to answer of self administered questionnaire 5)physician decided the patient is unsuitable to enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method percentage of patients with reducing treatment and maintaining control of asthma
- Secondary Outcome Measures
Name Time Method 1)pulmonary function using spirometry 2)questionnaire of asthma control 3)questionnaire of adverse effects 4)impulse oscillation system parameters and exhaled nitric oxide (only 2 ceters) 5)adverse events